Analyst Visit
Thyrocare Technologies Ltd has informed BSE regarding "Analyst Visit".23-02-2017
Analyst Visit
Thyrocare Technologies Ltd has informed BSE that Mr. Balvinder Singh, Analyst from Canara HSBC, would be having a meeting with the Company's Vice-President (Operations), Dr. Caesar Sengupta, and General Manager-Finance, Mr. Sachin Salvi, at the Company's Corporate Office, on February 09, 2017 by 5.00 P.M.07-02-2017
Outcome of Board Meeting
Thyrocare Technologies Ltd has informed BSE that the Board of Directors of the Company at their meeting held on January 28, 2017, have decided to discontinue, with immediate effect, the existing arrangement with Company's wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), by which the Company was sourcing PET-CT business for them against a fee of 20% of the amount charged by them.30-01-2017
Intimation of Conference Call
Thyrocare Technologies Ltd has informed BSE regarding "Intimation of Conference Call for the Indian and Overseas analysts".30-01-2017
Thyrocare Tech expands income and profits in an upbeat Q3
Pharmaceutical services company Thryocare Technologies reported strong results for Q3 this financial year, showing 25.4% growth in income compared to the same quarter last year. The total Q3 income of Rs. 71 crore for the quarter came with Rs. 15.3 crore net profit, a 42% profit growth for the quarter. The company has been operating with a low-cost, online driven and franchise model that has proved popular in large cities for diagnostic tests. The company has seen strong results for the past two quarters of FY17, and announced an interim dividend of Rs. 5 per share.29-01-2017
Fixes Record Date for Interim Dividend
Thyrocare Technologies Ltd has informed BSE that the Company has fixed February 09, 2017 as the Record Date for the purpose of Payment of Interim Dividend.29-01-2017